Back to Search
JACOB VEATCH, PHARMD
PHARMD
Pharmacist
NPI: 1952828972Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
2006021(CO)
Research & Publications (8)
Mitochondrial dysfunction leads to nuclear genome instability via an iron-sulfur cluster defect.
PMID 19563757·Cell·2009
8-other
Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.
PMID 19171714·J Clin Oncol·2009
3-trial
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
PMID 17369569·J Clin Oncol·2007
3-trial
Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
PMID 17102115·Ann N Y Acad Sci·2006
3-trial
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
PMID 16421427·J Clin Oncol·2006
3-trial
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
PMID 15197208·J Clin Oncol·2004
3-trial
Ku interacts with telomerase RNA to promote telomere addition at native and broken chromosome ends.
PMID 12975323·Genes Dev·2003
8-other
Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
PMID 11696644·J Nucl Med·2001
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 480 MAIN, BOX 429
NUCLA, CO 81424 - Phone
- (970) 864-2100
Quick Facts
- NPI
- 1952828972
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 8
Are you this provider?
Claim Your Profile